1Yates LR, Gerstung M, Knappskog S, et al. Subclonal diversification of primary breast cancer revealed by muhiregion sequencing [J]. Nat Med, 2015, 21(7) : 751-759.
2Garcia- Murillas I, Schiavon G, Weigeh B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer [J]. Sci Transl Med, 2015, 7(302) : 302ra133.
3Cox TR, Rumney RM, Schoof EM, et al. The hypoxic cancer secretome induces pre- metastatic bone lesions through lysyl oxidase [J]. Nature, 2015, 522(7554) : 106-110.
4Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy- induced antitumor immunity requires formyl peptide receptor 1 [J]. Science, 2015, 350(6263): 972-978.
5Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer [J]. Sci Transl Med, 2015, 7(313) : 313ra182.
6Nielsen TO, Jensen M- B, Gao D, et al. High risk premenopausal luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: Results from DBCG77B randomized trial [DB/OL]. SABCS, 2015 : Abstr S1-08.
7Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer [J]. N Engl J Med, 2015, 373(21) : 2005-2014.
8Harbeck N, Gluz O, Christgen M, et al. Final analysis Of WSG-ADAPT HER2+/HR+ phase II triM: Efficacy, safety,and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus Trastuzumab + endocrine therapy in HER2- positive hormone- receptor- positive early breast cancer [ DB/OL ]. SABCS, 2015 : Abstr $5-03.
9Chan A, Delaloge S, Holmes FA, et al. Neratinib after adjuvant chemotherapy and Trastuzumab in HER2- positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET) [J]. J Clin Oncol (Meeting Abstracts), 2015, 33(15s) : Abstr 508.
10Loi S, Drubay D, Adams S, et al. Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline- based chemotherapy [DB/OL]. SABCS, 2015 : Abstr S1-03. Turner NC, Ro J, Andr6 F, et al. Palbociclib in hormone- receptor-positive advanced breast cancer[J]. N Engl J Med, 2015, 373(3): 209-219.
